236 related articles for article (PubMed ID: 21082920)
1. FLT3 inhibitors in acute myeloid leukemia.
el-Shami K; Stone RM; Smith BD
Expert Rev Hematol; 2008 Dec; 1(2):153-60. PubMed ID: 21082920
[TBL] [Abstract][Full Text] [Related]
2. Lestaurtinib: a multi-targeted FLT3 inhibitor.
Fathi AT; Levis M
Expert Rev Hematol; 2009 Feb; 2(1):17-26. PubMed ID: 21082990
[TBL] [Abstract][Full Text] [Related]
3. FLT3 inhibitors for the treatment of acute myeloid leukemia.
Wiernik PH
Clin Adv Hematol Oncol; 2010 Jun; 8(6):429-36, 444. PubMed ID: 20733555
[TBL] [Abstract][Full Text] [Related]
4. FMS-like tyrosine kinase 3 in normal hematopoiesis and acute myeloid leukemia.
Parcells BW; Ikeda AK; Simms-Waldrip T; Moore TB; Sakamoto KM
Stem Cells; 2006 May; 24(5):1174-84. PubMed ID: 16410383
[TBL] [Abstract][Full Text] [Related]
5. Lestaurtinib, a multitargeted tyrosine kinase inhibitor: from bench to bedside.
Shabbir M; Stuart R
Expert Opin Investig Drugs; 2010 Mar; 19(3):427-36. PubMed ID: 20141349
[TBL] [Abstract][Full Text] [Related]
6. AEE788 is a vascular endothelial growth factor receptor tyrosine kinase inhibitor with antiproliferative and proapoptotic effects in acute myeloid leukemia.
Barbarroja N; Torres LA; Rodriguez-Ariza A; Valverde-Estepa A; Lopez-Sanchez LM; Ruiz-Limon P; Perez-Sanchez C; Carretero RM; Velasco F; López-Pedrera C
Exp Hematol; 2010 Aug; 38(8):641-52. PubMed ID: 20380868
[TBL] [Abstract][Full Text] [Related]
7. The clinical development of FLT3 inhibitors in acute myeloid leukemia.
Knapper S
Expert Opin Investig Drugs; 2011 Oct; 20(10):1377-95. PubMed ID: 21895538
[TBL] [Abstract][Full Text] [Related]
8. FLT3 inhibition in acute myeloid leukaemia.
Knapper S
Br J Haematol; 2007 Sep; 138(6):687-99. PubMed ID: 17655729
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of Flt3-activating mutations does not prevent constitutive activation of ERK/Akt/STAT pathways in some AML cells: a possible cause for the limited effectiveness of monotherapy with small-molecule inhibitors.
Siendones E; Barbarroja N; Torres LA; Buendía P; Velasco F; Dorado G; Torres A; López-Pedrera C
Hematol Oncol; 2007 Mar; 25(1):30-7. PubMed ID: 17128418
[TBL] [Abstract][Full Text] [Related]
10. The role of quizartinib in the treatment of acute myeloid leukemia.
Ostronoff F; Estey E
Expert Opin Investig Drugs; 2013 Dec; 22(12):1659-69. PubMed ID: 24070241
[TBL] [Abstract][Full Text] [Related]
11. Monitoring of FLT3 phosphorylation status and its response to drugs by flow cytometry in AML blast cells.
Grafone T; Palmisano M; Nicci C; Martelli AM; Emanuela O; Storti S; Baccarani M; Martinelli G
Hematol Oncol; 2008 Sep; 26(3):159-66. PubMed ID: 18383555
[TBL] [Abstract][Full Text] [Related]
12. 3,4-Diarylmaleimides-a novel class of kinase inhibitors-effectively induce apoptosis in FLT3-ITD-dependent cells.
Heidel FH; Mack TS; Razumovskaya E; Blum MC; Lipka DB; Ballaschk A; Kramb JP; Plutizki S; Rönnstrand L; Dannhardt G; Fischer T
Ann Hematol; 2012 Mar; 91(3):331-44. PubMed ID: 21881825
[TBL] [Abstract][Full Text] [Related]
13. FLT3 inhibitor KRN383 on xenografted human leukemic cells harboring FLT3-activating mutations FLT3 in AML: much more to learn about biology and optimal targeting.
Giles FJ
Leuk Res; 2006 Dec; 30(12):1469-70. PubMed ID: 16631251
[TBL] [Abstract][Full Text] [Related]
14. FLT3 inhibition: a moving and evolving target in acute myeloid leukaemia.
Leung AY; Man CH; Kwong YL
Leukemia; 2013 Feb; 27(2):260-8. PubMed ID: 22797419
[TBL] [Abstract][Full Text] [Related]
15. Tandutinib, an oral, small-molecule inhibitor of FLT3 for the treatment of AML and other cancer indications.
Cheng Y; Paz K
IDrugs; 2008 Jan; 11(1):46-56. PubMed ID: 18175263
[TBL] [Abstract][Full Text] [Related]
16. The Development of FLT3 Inhibitors in Acute Myeloid Leukemia.
Garcia JS; Stone RM
Hematol Oncol Clin North Am; 2017 Aug; 31(4):663-680. PubMed ID: 28673394
[TBL] [Abstract][Full Text] [Related]
17. [Mutations of growth factor receptor Flt3 in acute myeloid leukemia: transformation of myeloid cells by Ras-dependent and Ras-independent mechanisms].
Müller-Tidow C; Steur C; Mizuki M; Schwäble J; Brandts C; Berdel WE; Serve H
Dtsch Med Wochenschr; 2002 Oct; 127(42):2195-200. PubMed ID: 12397548
[TBL] [Abstract][Full Text] [Related]
18. FLT3 signaling and the development of inhibitors that target FLT3 kinase activity.
Langdon WY
Crit Rev Oncog; 2012; 17(2):199-209. PubMed ID: 22471708
[TBL] [Abstract][Full Text] [Related]
19. FMS-like tyrosine kinase 3 inhibitors: a patent review.
Lee J; Paek SM; Han SY
Expert Opin Ther Pat; 2011 Apr; 21(4):483-503. PubMed ID: 21323612
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic intervention in leukemias that express the activated fms-like tyrosine kinase 3 (FLT3): opportunities and challenges.
Sternberg DW; Licht JD
Curr Opin Hematol; 2005 Jan; 12(1):7-13. PubMed ID: 15604885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
